Download PDF
Semin Neurol 2016; 36(01): 047-053
DOI: 10.1055/s-0035-1571210
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Botulinum Toxin Treatment of Cervical Dystonia

Ian O. Bledsoe
1   Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois
,
Cynthia L. Comella
1   Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
11 February 2016 (online)

    Permissions and Reprints

Abstract

The use of botulinum toxin for the treatment of cervical dystonia (CD) was first reported in 1985. Since then, four commercially available formulations have been approved by the U.S. Food and Drug Administration for use in CD, including three botulinum toxin A formulations and one botulinum toxin B formulation. Recent clinical trials have generally demonstrated good efficacy and tolerability. Commonly reported side effects include dysphagia, muscle weakness, and dry mouth. Secondary nonresponse may develop, but the relationship of detected antibodies to clinical responsiveness remains unclear. Further research is needed into the treatment of complex subtypes of CD and the potential use of alternate botulinum toxin serotypes or subtypes with less immunogenic profiles.

Keywords

cervical dystonia - dystonia - botulinum toxin
 

  • References

  • 1 Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012; 27 (14) 1789-1796
    CrossrefPubMedGoogle Scholar
  • 2 Marras C, Van den Eeden SK, Fross RD , et al. Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology 2007; 69 (7) 676-680
    CrossrefPubMedGoogle Scholar
  • 3 Eichenseer SR, Stebbins GT, Comella CL. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord 2014; 20 (4) 405-408
    CrossrefPubMedGoogle Scholar
  • 4 Camfield L, Ben-Shlomo Y, Warner TT ; Epidemiological Study of Dystonia in Europe Collaborative Group. Impact of cervical dystonia on quality of life. Mov Disord 2002; 17 (4) 838-841
    CrossrefPubMedGoogle Scholar
  • 5 Dressler D, Rothwell JC. Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 2000; 43 (1) 13-16
    CrossrefPubMedGoogle Scholar
  • 6 Jankovic J, Adler CH, Charles D , et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 2015; 349 (1–2) 84-93
    CrossrefPubMedGoogle Scholar
  • 7 Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988; 50: 547-556
    PubMedGoogle Scholar
  • 8 Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985; 12 (4) 314-316
    CrossrefPubMedGoogle Scholar
  • 9 Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986; 2 (8501) 245-247
    PubMedGoogle Scholar
  • 10 Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989; 39 (1) 80-84
    CrossrefPubMedGoogle Scholar
  • 11 Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40 (8) 1213-1218
    CrossrefPubMedGoogle Scholar
  • 12 Gelb DJ, Yoshimura DM, Olney RK, Lowenstein DH, Aminoff MJ. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 1991; 29 (4) 370-376
    CrossrefPubMedGoogle Scholar
  • 13 Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF ; CD 140 Study Group. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012; 35 (5) 208-214
    CrossrefPubMedGoogle Scholar
  • 14 Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol 2014; 14: 91
    CrossrefPubMedGoogle Scholar
  • 15 Brans JW, Lindeboom R, Snoek JW , et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46 (4) 1066-1072
    CrossrefPubMedGoogle Scholar
  • 16 Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990; 53 (8) 640-643
    CrossrefPubMedGoogle Scholar
  • 17 Poewe W, Deuschl G, Nebe A , et al; German Dystonia Study Group. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 1998; 64 (1) 13-17
    CrossrefPubMedGoogle Scholar
  • 18 Truong D, Duane DD, Jankovic J , et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005; 20 (7) 783-791
    CrossrefPubMedGoogle Scholar
  • 19 Truong D, Brodsky M, Lew M , et al; Global Dysport Cervical Dystonia Study Group. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16 (5) 316-323
    CrossrefPubMedGoogle Scholar
  • 20 Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64 (11) 1949-1951
    CrossrefPubMedGoogle Scholar
  • 21 Dressler D, Tacik P, Saberi FA. Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm (Vienna) 2015; 122 (2) 297-300
    CrossrefPubMedGoogle Scholar
  • 22 Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S ; U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011; 308 (1–2) 103-109
    CrossrefPubMedGoogle Scholar
  • 23 Evidente VG, Fernandez HH, LeDoux MS , et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna) 2013; 120 (12) 1699-1707
    CrossrefPubMedGoogle Scholar
  • 24 Fernandez HH, Pappert EJ, Comella CL , et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naive subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y) 2013; 3
    PubMedGoogle Scholar
  • 25 Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry 2013; 84 (9) 1014-1019
    CrossrefPubMedGoogle Scholar
  • 26 Lew MF, Adornato BT, Duane DD , et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49 (3) 701-707
    CrossrefPubMedGoogle Scholar
  • 27 Brashear A, Lew MF, Dykstra DD , et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53 (7) 1439-1446
    CrossrefPubMedGoogle Scholar
  • 28 Brin MF, Lew MF, Adler CH , et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53 (7) 1431-1438
    CrossrefPubMedGoogle Scholar
  • 29 Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A—resistant patients. Mov Disord 1996; 11 (2) 181-184
    CrossrefPubMedGoogle Scholar
  • 30 Chen R, Karp BI, Hallett M. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 1998; 51 (5) 1494-1496
    CrossrefPubMedGoogle Scholar
  • 31 Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998; 64 (5) 577-580
    CrossrefPubMedGoogle Scholar
  • 32 Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004; 19 (Suppl. 08) S109-S115
    CrossrefPubMedGoogle Scholar
  • 33 Comella CL, Jankovic J, Shannon KM , et al; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65 (9) 1423-1429
    CrossrefPubMedGoogle Scholar
  • 34 Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005; 65 (5) 765-767
    CrossrefPubMedGoogle Scholar
  • 35 Pappert EJ, Germanson T ; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 2008; 23 (4) 510-517
    CrossrefPubMedGoogle Scholar
  • 36 Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007; 29 (7) 1325-1337
    CrossrefPubMedGoogle Scholar
  • 37 Nijmeijer SW, Koelman JH, Kamphuis DJ, Tijssen MA. Muscle selection for treatment of cervical dystonia with botulinum toxin—a systematic review. Parkinsonism Relat Disord 2012; 18 (6) 731-736
    CrossrefPubMedGoogle Scholar
  • 38 Van Gerpen JA, Matsumoto JY, Ahlskog JE, Maraganore DM, McManis PG. Utility of an EMG mapping study in treating cervical dystonia. Muscle Nerve 2000; 23 (11) 1752-1756
    CrossrefPubMedGoogle Scholar
  • 39 Brans JW, de Boer IP, Aramideh M, Ongerboer de Visser BW, Speelman JD. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol 1995; 242 (8) 529-534
    CrossrefPubMedGoogle Scholar
  • 40 Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42 (4) 878-882
    CrossrefPubMedGoogle Scholar
  • 41 Werdelin L, Dalager T, Fuglsang-Frederiksen A , et al. The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study. Clin Neurophysiol 2011; 122 (11) 2305-2309
    CrossrefPubMedGoogle Scholar
  • 42 Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 2006; 21 (10) 1737-1741
    CrossrefPubMedGoogle Scholar
  • 43 Sung DH, Choi JY, Kim DH , et al. Localization of dystonic muscles with 18F-FDG PET/CT in idiopathic cervical dystonia. J Nucl Med 2007; 48 (11) 1790-1795
    CrossrefPubMedGoogle Scholar
  • 44 Lee IH, Yoon YC, Sung DH, Kwon JW, Jung JY. Initial experience with imaging-guided intramuscular botulinum toxin injection in patients with idiopathic cervical dystonia. AJR Am J Roentgenol 2009; 192 (4) 996-1001
    CrossrefPubMedGoogle Scholar
  • 45 Hong JS, Sathe GG, Niyonkuru C, Munin MC. Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia. Muscle Nerve 2012; 46 (4) 535-539
    CrossrefPubMedGoogle Scholar
  • 46 Schramm A, Baumer T, Fietzek U , et al. Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. J Neural Transm 2015; 122 (10) 1457-1463
    CrossrefPubMedGoogle Scholar
  • 47 Kessler KR, Skutta M, Benecke R ; German Dystonia Study Group. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999; 246 (4) 265-274
    CrossrefPubMedGoogle Scholar
  • 48 Ruiz PJ, Castrillo JC, Burguera JA , et al. Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 2011; 258 (6) 1055-1057
    CrossrefPubMedGoogle Scholar
  • 49 Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60 (7) 1186-1188
    CrossrefPubMedGoogle Scholar
  • 50 Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 2012; 35 (5) 215-223
    CrossrefPubMedGoogle Scholar
  • 51 Bhidayasiri R. Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 2011; 17 (Suppl. 01) S20-S24
    CrossrefPubMedGoogle Scholar
  • 52 Papapetropoulos S, Baez S, Zitser J, Sengun C, Singer C. Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. Eur Neurol 2008; 59 (1–2) 71-75
    CrossrefPubMedGoogle Scholar
  • 53 Kane CD, Nuss JE, Bavari S. Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014). Expert Opin Ther Pat 2015; 25 (6) 675-690
    CrossrefPubMedGoogle Scholar
  • 54 Odergren T, Hjaltason H, Kaakkola S , et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64 (1) 6-12
    CrossrefPubMedGoogle Scholar